Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9682000rdf:typepubmed:Citationlld:pubmed
pubmed-article:9682000lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C0016055lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C0021757lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C1333568lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C0001511lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C1522457lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C0209606lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C1138422lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C0249989lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:9682000lifeskim:mentionsumls-concept:C1709634lld:lifeskim
pubmed-article:9682000pubmed:issue1lld:pubmed
pubmed-article:9682000pubmed:dateCreated1998-8-20lld:pubmed
pubmed-article:9682000pubmed:abstractTextAdhesion of hematopoietic cells to extracellular matrix components is important for blood cell development. However, little is known regarding the potential influence of IL-3 on this process for precursor B cells and Flt3-ligand has not yet been implicated in induction of adhesion of any blood cell types to extracellular matrix components. Therefore, we examined the characteristics of cytokine-induced cell adhesion to fibronectin (FN), using as a model the murine precursor B cell line, Baf3, a factor-dependent cell line requiring IL-3 for both growth and survival. Since factor-dependent hematopoietic cell lines expressing Flt3 receptor are extremely rare, we also studied Baf3/Flt3, a subline of Baf3 transduced with the Flt3 receptor gene. IL-3 induced adhesion of Baf3 and Baf3/Flt3 cells to FN, while Flt3-ligand induced adhesion of Baf3/Flt3 cells only. Whereas both Baf3 and Baf3/Flt3 cells expressed VLA-4 and -5 integrins as FN receptors, expression levels of VLA-4 and -5 were not affected by IL-3 or Flt3-ligand treatment. However, blocking experiments using anti-integrin antibodies showed that cytokine-induced adhesion of cells depended on both VLA-4 and -5 suggesting that IL-3 and Flt3-ligand activated these integrins. PI-3 kinase inhibitor wortmannin, PKC inhibitor H-7, or PKA inhibitor HA1004 did not suppress adhesion induced by IL-3 or Flt3-ligand; in contrast, PLC inhibitor U-73122 did suppress adhesion, suggesting the possibility that PLC, but not PI-3 kinase, PKC, or PKA, may be involved in this process. Since it is known that IL-3 and Flt3-ligand receptors are expressed on precursor B cells, and these receptors are downregulated during B cell maturation of primary cells, the induction of precursor B cell adhesion to FN by IL-3 and Flt3-ligand may contribute a mechanism by which precursor B cells adhere to bone marrow stroma, thereby influencing their development.lld:pubmed
pubmed-article:9682000pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:languageenglld:pubmed
pubmed-article:9682000pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:citationSubsetIMlld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9682000pubmed:statusMEDLINElld:pubmed
pubmed-article:9682000pubmed:monthJullld:pubmed
pubmed-article:9682000pubmed:issn0008-8749lld:pubmed
pubmed-article:9682000pubmed:authorpubmed-author:BroxmeyerH...lld:pubmed
pubmed-article:9682000pubmed:authorpubmed-author:MantenAAlld:pubmed
pubmed-article:9682000pubmed:authorpubmed-author:RitchieAAlld:pubmed
pubmed-article:9682000pubmed:authorpubmed-author:AnzaiNNlld:pubmed
pubmed-article:9682000pubmed:authorpubmed-author:ShibayamaHHlld:pubmed
pubmed-article:9682000pubmed:authorpubmed-author:ZhangSSlld:pubmed
pubmed-article:9682000pubmed:issnTypePrintlld:pubmed
pubmed-article:9682000pubmed:day10lld:pubmed
pubmed-article:9682000pubmed:volume187lld:pubmed
pubmed-article:9682000pubmed:ownerNLMlld:pubmed
pubmed-article:9682000pubmed:authorsCompleteYlld:pubmed
pubmed-article:9682000pubmed:pagination27-33lld:pubmed
pubmed-article:9682000pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:meshHeadingpubmed-meshheading:9682000-...lld:pubmed
pubmed-article:9682000pubmed:year1998lld:pubmed
pubmed-article:9682000pubmed:articleTitleInterleukin-3 and Flt3-ligand induce adhesion of Baf3/Flt3 precursor B-lymphoid cells to fibronectin via activation of VLA-4 and VLA-5.lld:pubmed
pubmed-article:9682000pubmed:affiliationDepartment of Microbiology/Immunology, Indiana University School of Medicine, Indianapolis 46202, USA.lld:pubmed
pubmed-article:9682000pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9682000pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9682000lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9682000lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9682000lld:pubmed